0.85Open0.85Pre Close0 Volume10 Open Interest3.00Strike Price0.00Turnover117.82%IV16.67%PremiumAug 16, 2024Expiry Date0.42Intrinsic Value100Multiplier19DDays to Expiry0.43Extrinsic Value100Contract SizeAmericanOptions Type-0.6607Delta0.5272Gamma4.69Leverage Ratio-0.0064Theta-0.0010Rho-3.10Eff Leverage0.0022Vega
Corvus Pharmaceuticals Stock Discussion
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024
Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024
Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefin...
NEWS
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
NEWS
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
No comment yet